2024MAY03: Our hosting provider has resolved some DB connectivity issues. We may experience some more outages as the issue is resolved. We apologize for the inconvenience. Dismiss and don't show again

Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Thioaptamer conjugated liposomes for tumor vasculature targeting.

Oncotarget | 2011

Recent developments in multi-functional nanoparticles offer a great potential for targeted delivery of therapeutic compounds and imaging contrast agents to specific cell types, in turn, enhancing therapeutic effect and minimizing side effects. Despite the promise, site specific delivery carriers have not been translated into clinical reality. In this study, we have developed long circulating liposomes with the outer surface decorated with thioated oligonucleotide aptamer (thioaptamer) against E-selectin (ESTA) and evaluated the targeting efficacy and PK parameters. In vitro targeting studies using Human Umbilical Cord Vein Endothelial Cell (HUVEC) demonstrated efficient and rapid uptake of the ESTA conjugated liposomes (ESTA-lip). In vivo, the intravenous administration of ESTA-lip resulted in their accumulation at the tumor vasculature of breast tumor xenografts without shortening the circulation half-life. The study presented here represents an exemplary use of thioaptamer and liposome and opens the door to testing various combinations of thioaptamer and nanocarriers that can be constructed to target multiple cancer types and tumor components for delivery of both therapeutics and imaging agent.

Pubmed ID: 21666286 RIS Download

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: NHLBI NIH HHS, United States
    Id: N01HV28184
  • Agency: NIAID NIH HHS, United States
    Id: HHSN272200800048C
  • Agency: NIGMS NIH HHS, United States
    Id: GM 084552
  • Agency: NHLBI NIH HHS, United States
    Id: N01-HV-28184
  • Agency: NCI NIH HHS, United States
    Id: U54 CA151668
  • Agency: NCI NIH HHS, United States
    Id: U54CA151668
  • Agency: NIGMS NIH HHS, United States
    Id: R44 GM084552
  • Agency: NIAID NIH HHS, United States
    Id: R01 AI027744
  • Agency: NIAID NIH HHS, United States
    Id: AI 27744
  • Agency: NIGMS NIH HHS, United States
    Id: R43 GM084552

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


HUVEC-C (tool)

RRID:CVCL_2959

Cell line HUVEC-C is a Finite cell line with a species of origin Homo sapiens

View all literature mentions